Stock Track | Burning Rock Biotech (BNR) Surges 5.04% Pre-market, Extending Recent Rally on Positive Developments

Stock Track

Oct 28

Shares of Burning Rock Biotech Limited (BNR) soared 5.04% in pre-market trading on Tuesday, continuing the stock's impressive rally that has seen it gain over 60% in the past week. This surge comes on the heels of a series of positive developments for the company, including promising research presentations and progress towards profitability.

The recent upward momentum began on October 21 when Burning Rock released a compilation of research findings presented at international academic conferences. These presentations, focusing on advanced DNA/RNA co-detection and low-abundance circulating tumor DNA (ctDNA) detection technologies, sparked investor interest. Since then, the stock has experienced five consecutive days of gains, cumulatively rising by 62.31%.

Driving this sustained rally are several key factors. Burning Rock's Q2 2025 results showed improving financials, with revenue up 10% year-over-year and a significant narrowing of net losses. The company's collaboration with AstraZeneca on the OncoCompass® Plus Prime ctDNA detection product and the recent approval of OncoGuide OncoScreen Plus CDx in Japan as a companion diagnostic for advanced breast cancer treatment have also bolstered investor confidence. These developments, combined with the company's progress towards profitability and strategic partnerships, appear to be fueling optimism about Burning Rock's future prospects in the competitive biotech sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175238141"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175238141\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175238141?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175238141","market":"nz","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech (BNR) Surges 5.04% Pre-market, Extending Recent Rally on Positive Developments","media":"Stock Track","content":"<p>Shares of Burning Rock Biotech Limited (BNR) soared 5.04% in pre-market trading on Tuesday, continuing the stock's impressive rally that has seen it gain over 60% in the past week. This surge comes on the heels of a series of positive developments for the company, including promising research presentations and progress towards profitability.</p>\n\n<p>The recent upward momentum began on October 21 when Burning Rock released a compilation of research findings presented at international academic conferences. These presentations, focusing on advanced DNA/RNA co-detection and low-abundance circulating tumor DNA (ctDNA) detection technologies, sparked investor interest. Since then, the stock has experienced five consecutive days of gains, cumulatively rising by 62.31%.</p>\n\n<p>Driving this sustained rally are several key factors. Burning Rock's Q2 2025 results showed improving financials, with revenue up 10% year-over-year and a significant narrowing of net losses. The company's collaboration with AstraZeneca on the OncoCompass® Plus Prime ctDNA detection product and the recent approval of OncoGuide OncoScreen Plus CDx in Japan as a companion diagnostic for advanced breast cancer treatment have also bolstered investor confidence. These developments, combined with the company's progress towards profitability and strategic partnerships, appear to be fueling optimism about Burning Rock's future prospects in the competitive biotech sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech (BNR) Surges 5.04% Pre-market, Extending Recent Rally on Positive Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech (BNR) Surges 5.04% Pre-market, Extending Recent Rally on Positive Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-28 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Burning Rock Biotech Limited (BNR) soared 5.04% in pre-market trading on Tuesday, continuing the stock's impressive rally that has seen it gain over 60% in the past week. This surge comes on the heels of a series of positive developments for the company, including promising research presentations and progress towards profitability.</p>\n\n<p>The recent upward momentum began on October 21 when Burning Rock released a compilation of research findings presented at international academic conferences. These presentations, focusing on advanced DNA/RNA co-detection and low-abundance circulating tumor DNA (ctDNA) detection technologies, sparked investor interest. Since then, the stock has experienced five consecutive days of gains, cumulatively rising by 62.31%.</p>\n\n<p>Driving this sustained rally are several key factors. Burning Rock's Q2 2025 results showed improving financials, with revenue up 10% year-over-year and a significant narrowing of net losses. The company's collaboration with AstraZeneca on the OncoCompass® Plus Prime ctDNA detection product and the recent approval of OncoGuide OncoScreen Plus CDx in Japan as a companion diagnostic for advanced breast cancer treatment have also bolstered investor confidence. These developments, combined with the company's progress towards profitability and strategic partnerships, appear to be fueling optimism about Burning Rock's future prospects in the competitive biotech sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1175238141","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175238141","pubTimestamp":1761658000,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Burning Rock Biotech Limited (BNR) soared 5.04% in pre-market trading on Tuesday, continuing the stock's impressive rally that has seen it gain over 60% in the past week. This surge comes...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股追踪|燃石生物(BNR)盘前大涨5.04%因利好消息延续近期涨势","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Shares of Burning Rock Biotech Limited (BNR) soared 5.04% in pre-market trading on Tuesday, continuing the stock's impressive rally that has seen it gain over 60% in the past week. This surge comes on the heels of a series of positive developments for the company, including promising research presentations and progress towards profitability.\nThe recent upward momentum began on October 21 when Burning Rock released a compilation of research findings presented at international academic conferences. These presentations, focusing on advanced DNA/RNA co-detection and low-abundance circulating tumor DNA (ctDNA) detection technologies, sparked investor interest. Since then, the stock has experienced five consecutive days of gains, cumulatively rising by 62.31%.\nDriving this sustained rally are several key factors. Burning Rock's Q2 2025 results showed improving financials, with revenue up 10% year-over-year and a significant narrowing of net losses. The company's collaboration with AstraZeneca on the OncoCompass® Plus Prime ctDNA detection product and the recent approval of OncoGuide OncoScreen Plus CDx in Japan as a companion diagnostic for advanced breast cancer treatment have also bolstered investor confidence. These developments, combined with the company's progress towards profitability and strategic partnerships, appear to be fueling optimism about Burning Rock's future prospects in the competitive biotech sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}